Targeting Apoptosis in Autoimmune Hepatitis

Digestive Diseases and Sciences

Volumn 59, Issue 12, 2014, Pages 2890-2904

  Czaja, Albert J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Apoptosis; Autoimmune hepatitis; Interventions; Pathogenesis

Indexed keywords

APOPTOSOME; AUTOANTIGEN; CASPASE 3; CASPASE 7; CASPASE 8; CASPASE INHIBITOR; CELL NUCLEUS DNA; DEATH RECEPTOR; FAS ANTIGEN; FAS LIGAND; OLIGONUCLEOTIDE; PROTEIN BCL 2; TOLL LIKE RECEPTOR; X LINKED INHIBITOR OF APOPTOSIS; ENZYME INHIBITOR; IMMUNOLOGIC FACTOR;

APOPTOSIS; AUTOIMMUNE HEPATITIS; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; HUMAN; IMMUNE RESPONSE; MEMBRANE PERMEABILITY; MITOCHONDRIAL MEMBRANE; NONHUMAN; PROMOTER REGION; REVIEW; SURVIVAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; HEPATITIS, AUTOIMMUNE; METABOLISM; PATHOLOGY;

APOPTOSIS; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOLOGIC FACTORS;

EID: 84912528717     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-014-3284-2     Document Type: Review

References (179)

1. Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51:2193–2213.
2. Kerr JF, Cooksley WG, Searle J, et al. The nature of piecemeal necrosis in chronic active hepatitis. Lancet. 1979;2:827–828.
3. Dong Z, Saikumar P, Weinberg JM, Venkatachalam MA. Internucleosomal DNA cleavage triggered by plasma membrane damage during necrotic cell death. Involvement of serine but not cysteine proteases. Am J Pathol. 1997;151:1205–1213.
4. Afford S, Randhawa S. Apoptosis. Mol Pathol. 2000;53:55–63.
5. Czaja AJ. Autoimmune hepatitis. Part A: pathogenesis. Expert Rev Gastroenterol Hepatol. 2007;1:113–128.
6. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972;26:239–257.
7. Kerr JF. Shrinkage necrosis: a distinct mode of cellular death. J Pathol. 1971;105:13–20.
8. Wyllie AH, Morris RG, Smith AL, Dunlop D. Chromatin cleavage in apoptosis: association with condensed chromatin morphology and dependence on macromolecular synthesis. J Pathol. 1984;142:67–77.
9. Berg CP, Stein GM, Keppeler H, et al. Apoptosis-associated antigens recognized by autoantibodies in patients with the autoimmune liver disease primary biliary cirrhosis. Apoptosis. 2008;13:63–75.
10. Zampieri S, Degen W, Ghiradello A, Doria A, van Venrooij WJ. Dephosphorylation of autoantigenic ribosomal P proteins during Fas-L induced apoptosis: a possible trigger for the development of the autoimmune response in patients with systemic lupus erythematosus. Ann Rheum Dis. 2001;60:72–76.
11. Greidinger EL, Foecking MF, Ranatunga S, Hoffman RW. Apoptotic U1-70 kd is antigenically distinct from the intact form of the U1-70-kd molecule. Arthritis Rheum. 2002;46:1264–1269.
12. Dieker JW, Fransen JH, van Bavel CC, et al. Apoptosis-induced acetylation of histones is pathogenic in systemic lupus erythematosus. Arthritis Rheum. 2007;56:1921–1933.
13. Rosen A, Casciola-Rosen L. Autoantigens in systemic autoimmunity: critical partner in pathogenesis. J Intern Med. 2009;265:625–631.
14. Savill J, Fadok V. Corpse clearance defines the meaning of cell death. Nature. 2000;407:784–788.
15. Grimsley C, Ravichandran KS. Cues for apoptotic cell engulfment: eat-me, don’t eat-me and come-get-me signals. Trends Cell Biol. 2003;13:648–656.
16. Henson PM, Hume DA. Apoptotic cell removal in development and tissue homeostasis. Trends Immunol. 2006;27:244–250.
17. A-Gonzalez N, Bensinger SJ, Hong C, et al. Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR. Immunity. 2009;31:245–258.
18. Green DR, Reed JC. Mitochondria and apoptosis. Science. 1998;281:1309–1312.
19. Kanzler S, Galle PR. Apoptosis and the liver. Semin Cancer Biol. 2000;10:173–184.
20. Canbay A, Feldstein AE, Higuchi H, et al. Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology. 2003;38:1188–1198.
21. Zhan SS, Jiang JX, Wu J, et al. Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and is associated with liver fibrosis in vivo. Hepatology. 2006;43:435–443.
22. Ogawa S, Sakaguchi K, Takaki A, et al. Increase in CD95 (Fas/APO-1)-positive CD4+ and CD8+ T cells in peripheral blood derived from patients with autoimmune hepatitis or chronic hepatitis C with autoimmune phenomena. J Gastroenterol Hepatol. 2000;15:69–75.
23. Fox CK, Furtwaengler A, Nepomuceno RR, Martinez OM, Krams SM. Apoptotic pathways in primary biliary cirrhosis and autoimmune hepatitis. Liver. 2001;21:272–279.
24. Bai J, Odin JA. Apoptosis and the liver: relation to autoimmunity and related conditions. Autoimmun Rev. 2003;2:36–42.
25. Patel T, Gores GJ. Apoptosis and hepatobiliary disease. Hepatology. 1995;21:1725–1741.
26. Thatte U, Dahanukar S. Apoptosis: clinical relevance and pharmacological manipulation. Drugs. 1997;54:511–532.
27. D’Amelio M, Tino E, Cecconi F. The apoptosome: emerging insights and new potential targets for drug design. Pharm Res. 2008;25:740–751.
28. O’Reilly LA, Strasser A. Apoptosis and autoimmune disease. Inflamm Res. 1999;48:5–21.
29. Neuman MG. Apoptosis in diseases of the liver. Crit Rev Clin Lab Sci. 2001;38:109–166.
30. Beland K, Lapierre P, Djilali-Saiah I, Alvarez F. Liver restores immune homeostasis after local inflammation despite the presence of autoreactive T cells. PLoS One. 2012;7:e48192.
31. Goldstein JC, Waterhouse NJ, Juin P, Evan GI, Green DR. The coordinate release of cytochrome c during apoptosis is rapid, complete and kinetically invariant. Nat Cell Biol. 2000;2:156–162.
32. Tsujimoto Y, Nakagawa T, Shimizu S. Mitochondrial membrane permeability transition and cell death. Biochim Biophys Acta. 2006;1757:1297–1300.
33. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science. 1998;281:1322–1326.
34. Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev. 2007;87:99–163.
35. Ren D, Tu HC, Kim H, et al. BID, BIM, and PUMA are essential for activation of the BAX- and BAK-dependent cell death program. Science. 2010;330:1390–1393.
36. Ekert PG, Read SH, Silke J, et al. Apaf-1 and caspase-9 accelerate apoptosis, but do not determine whether factor-deprived or drug-treated cells die. J Cell Biol. 2004;165:835–842.
37. Rodriguez J, Lazebnik Y. Caspase-9 and APAF-1 form an active holoenzyme. Genes Dev. 1999;13:3179–3184.
38. Guicciardi ME, Gores GJ. Apoptosis as a mechanism for liver disease progression. Semin Liver Dis. 2010;30:402–410.
39. Faubion WA, Gores GJ. Death receptors in liver biology and pathobiology. Hepatology. 1999;29:1–4.
40. Desbarats J, Duke RC, Newell MK. Newly discovered role for Fas ligand in the cell-cycle arrest of CD4+ T cells. Nat Med. 1998;4:1377–1382.
41. Nagata S. Apoptosis mediated by the Fas system. Prog Mol Subcell Biol. 1996;16:87–103.
42. Wajant H. Death receptors. Essays Biochem. 2003;39:53–71.
43. Oberst A, Pop C, Tremblay AG, et al. Inducible dimerization and inducible cleavage reveal a requirement for both processes in caspase-8 activation. J Biol Chem. 2010;285:16632–16642.
44. Peter ME, Krammer PH. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ. 2003;10:26–35.
45. Fuentes-Prior P, Salvesen GS. The protein structures that shape caspase activity, specificity, activation and inhibition. Biochem J. 2004;384:201–232.
46. Ma S, Hockings C, Anwari K, et al. Assembly of the Bak apoptotic pore: a critical role for the Bak protein alpha6 helix in the multimerization of homodimers during apoptosis. J Biol Chem. 2013;288:26027–26038.
47. Grenet J, Teitz T, Wei T, Valentine V, Kidd VJ. Structure and chromosome localization of the human CASP8 gene. Gene. 1999;226:225–232.
48. Wang J, Chun HJ, Wong W, Spencer DM, Lenardo MJ. Caspase-10 is an initiator caspase in death receptor signaling. Proc Natl Acad Sci USA. 2001;98:13884–13888.
49. Muhlethaler-Mottet A, Flahaut M, Bourloud KB, et al. Individual caspase-10 isoforms play distinct and opposing roles in the initiation of death receptor-mediated tumour cell apoptosis. Cell Death Dis. 2011;2:e125.
50. Kischkel FC, Lawrence DA, Tinel A, et al. Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J Biol Chem. 2001;276:46639–46646.
51. Sprick MR, Rieser E, Stahl H, et al. Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8. EMBO J. 2002;21:4520–4530.
52. Fischer U, Stroh C, Schulze-Osthoff K. Unique and overlapping substrate specificities of caspase-8 and caspase-10. Oncogene. 2006;25:152–159.
53. Wachmann K, Pop C, van Raam BJ, et al. Activation and specificity of human caspase-10. Biochemistry. 2010;49:8307–8315.
54. Kahraman A, Gerken G, Canbay A. Apoptosis in immune-mediated liver diseases. Dig Dis. 2010;28:144–149.
55. Kahraman A, Fingas CD, Syn WK, Gerken G, Canbay A. Role of stress-induced NKG2D ligands in liver diseases. Liver Int. 2012;32:370–382.
56. Czaja AJ. Hepatic inflammation and progressive liver fibrosis in chronic liver disease. World J Gastroenterol. 2014;20:2515–2532.
57. Czaja AJ. Review article: Chemokines as orchestrators of autoimmune hepatitis and potential therapeutic targets. Aliment Pharmacol Ther. 2014;40:261–279.
58. Canbay A, Friedman S, Gores GJ. Apoptosis: the nexus of liver injury and fibrosis. Hepatology. 2004;39:273–278.
59. Bechmann LP, Jochum C, Kocabayoglu P, et al. Cytokeratin 18-based modification of the MELD score improves prediction of spontaneous survival after acute liver injury. J Hepatol. 2010;53:639–647.
60. Cheng J, Zhou T, Liu C, et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science. 1994;263:1759–1762.
61. Cascino I, Fiucci G, Papoff G, Ruberti G. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J Immunol. 1995;154:2706–2713.
62. Eichhorst ST. Modulation of apoptosis as a target for liver disease. Expert Opin Ther Targets. 2005;9:83–99.
63. Hiraide A, Imazeki F, Yokosuka O, et al. Fas polymorphisms influence susceptibility to autoimmune hepatitis. Am J Gastroenterol. 2005;100:1322–1329.
64. Inazawa J, Itoh N, Abe T, Nagata S. Assignment of the human Fas antigen gene (Fas) to 10q24.1. Genomics. 1992;14:821–822.
65. Agarwal K, Czaja AJ, Donaldson PT. A functional Fas promoter polymorphism is associated with a severe phenotype in type 1 autoimmune hepatitis characterized by early development of cirrhosis. Tissue Antigens. 2007;69:227–235.
66. Ichiki Y, Aoki CA, Bowlus CL, et al. T cell immunity in autoimmune hepatitis. Autoimmun Rev. 2005;4:315–321.
67. Zipp F, Weller M, Calabresi PA, et al. Increased serum levels of soluble CD95 (APO-1/Fas) in relapsing-remitting multiple sclerosis. Ann Neurol. 1998;43:116–120.
68. Matlin AJ, Clark F, Smith CW. Understanding alternative splicing: towards a cellular code. Nat Rev Mol Cell Biol. 2005;6:386–398.
69. Jodo S, Kobayashi S, Kayagaki N, et al. Serum levels of soluble Fas/APO-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases. Clin Exp Immunol. 1997;107:89–95.
70. Fujihara T, Takeuchi T, Tsubota K, et al. Serum soluble Fas/APO-1 is increased in patients with primary Sjogren’s syndrome. Clin Rheumatol. 1998;17:496–499.
71. Jodo S, Kobayashi S, Nakajima Y, et al. Elevated serum levels of soluble Fas/APO-1 (CD95) in patients with hepatocellular carcinoma. Clin Exp Immunol. 1998;112:166–171.
72. Midis GP, Shen Y, Owen-Schaub LB. Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy. Cancer Res. 1996;56:3870–3874.
73. Ueno T, Toi M, Tominaga T. Circulating soluble Fas concentration in breast cancer patients. Clin Cancer Res. 1999;5:3529–3533.
74. Ugurel S, Rappl G, Tilgen W, Reinhold U. Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients. Clin Cancer Res. 2001;7:1282–1286.
75. Wyllie AH, Arends MJ, Morris RG, Walker SW, Evan G. The apoptosis endonuclease and its regulation. Semin Immunol. 1992;4:389–397.
76. Wyllie AH. Apoptosis (the 1992 Frank Rose Memorial Lecture). Br J Cancer. 1993;67:205–208.
77. Ochi M, Ohdan H, Mitsuta H, et al. Liver NK cells expressing TRAIL are toxic against self hepatocytes in mice. Hepatology. 2004;39:1321–1331.
78. Kahraman A, Schlattjan M, Kocabayoglu P, et al. Major histocompatibility complex class I-related chains A and B (MIC A/B): a novel role in nonalcoholic steatohepatitis. Hepatology. 2010;51:92–102.
79. Kohga K, Takehara T, Tatsumi T, et al. Serum levels of soluble major histocompatibility complex (MHC) class I-related chain A in patients with chronic liver diseases and changes during transcatheter arterial embolization for hepatocellular carcinoma. Cancer Sci. 2008;99:1643–1649.
80. Holdenrieder S, Eichhorn P, Beuers U, et al. Soluble NKG2D ligands in hepatic autoimmune diseases and in benign diseases involved in marker metabolism. Anticancer Res. 2007;27:2041–2045.
81. Norris S, Kondeatis E, Collins R, et al. Mapping MHC-encoded susceptibility and resistance in primary sclerosing cholangitis: the role of MICA polymorphism. Gastroenterology. 2001;120:1475–1482.
82. Cox ST, Madrigal JA, Saudemont A. Diversity and characterization of polymorphic 5′ promoter haplotypes of MICA and MICB genes. Tissue Antigens. 2014. doi:10.1111/tan.12400.
83. Hill MM, Adrain C, Duriez PJ, Creagh EM, Martin SJ. Analysis of the composition, assembly kinetics and activity of native Apaf-1 apoptosomes. EMBO J. 2004;23:2134–2145.
84. Miyazaki K, Yoshida H, Sasaki M, et al. Caspase-independent cell death and mitochondrial disruptions observed in the Apaf1-deficient cells. J Biochem. 2001;129:963–969.
85. Riedl SJ, Li W, Chao Y, Schwarzenbacher R, Shi Y. Structure of the apoptotic protease-activating factor 1 bound to ADP. Nature. 2005;434:926–933.
86. Pop C, Timmer J, Sperandio S, Salvesen GS. The apoptosome activates caspase-9 by dimerization. Mol Cell. 2006;22:269–275.
87. Pandey P, Saleh A, Nakazawa A, et al. Negative regulation of cytochrome c-mediated oligomerization of Apaf-1 and activation of procaspase-9 by heat shock protein 90. EMBO J. 2000;19:4310–4322.
88. Saleh A, Srinivasula SM, Balkir L, Robbins PD, Alnemri ES. Negative regulation of the Apaf-1 apoptosome by Hsp70. Nat Cell Biol. 2000;2:476–483.
89. Beere HM. Death versus survival: functional interaction between the apoptotic and stress-inducible heat shock protein pathways. J Clin Invest. 2005;115:2633–2639.
90. Chandra D, Bratton SB, Person MD, et al. Intracellular nucleotides act as critical prosurvival factors by binding to cytochrome C and inhibiting apoptosome. Cell. 2006;125:1333–1346.
91. Pop C, Salvesen GS. Human caspases: activation, specificity, and regulation. J Biol Chem. 2009;284:21777–21781.
92. Schimmer AD, Dalili S, Batey RA, Riedl SJ. Targeting XIAP for the treatment of malignancy. Cell Death Differ. 2006;13:179–188.
93. Eckelman BP, Salvesen GS, Scott FL. Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep. 2006;7:988–994.
94. Pathan N, Marusawa H, Krajewska M, et al. TUCAN, an antiapoptotic caspase-associated recruitment domain family protein overexpressed in cancer. J Biol Chem. 2001;276:32220–32229.
95. Yamamoto M, Torigoe T, Kamiguchi K, et al. A novel isoform of TUCAN is overexpressed in human cancer tissues and suppresses both caspase-8- and caspase-9-mediated apoptosis. Cancer Res. 2005;65:8706–8714.
96. Verhagen AM, Silke J, Ekert PG, et al. HtrA2 promotes cell death through its serine protease activity and its ability to antagonize inhibitor of apoptosis proteins. J Biol Chem. 2002;277:445–454.
97. Sharief MK, Noori MA, Zoukos Y. Reduced expression of the inhibitor of apoptosis proteins in T cells from patients with multiple sclerosis following interferon-beta therapy. J Neuroimmunol. 2002;129:224–231.
98. Waiczies S, Weber A, Lunemann JD, et al. Elevated Bcl-X(L) levels correlate with T cell survival in multiple sclerosis. J Neuroimmunol. 2002;126:213–220.
99. Semra YK, Seidi OA, Sharief MK. Disease activity in multiple sclerosis correlates with T lymphocyte expression of the inhibitor of apoptosis proteins. J Neuroimmunol. 2002;122:159–166.
100. Semra YK, Seidi OA, Sharief MK. Overexpression of the apoptosis inhibitor FLIP in T cells correlates with disease activity in multiple sclerosis. J Neuroimmunol. 2001;113:268–274.
101. Bagnoli M, Canevari S, Mezzanzanica D. Cellular FLICE-inhibitory protein (c-FLIP) signalling: a key regulator of receptor-mediated apoptosis in physiologic context and in cancer. Int J Biochem Cell Biol. 2010;42:210–213.
102. Safa AR. c-FLIP, a master anti-apoptotic regulator. Exp Oncol. 2012;34:176–184.
103. Piao X, Komazawa-Sakon S, Nishina T, et al. c-FLIP maintains tissue homeostasis by preventing apoptosis and programmed necrosis. Sci Signal. 2012;5:ra93.
104. Bona G, Defranco S, Chiocchetti A, et al. Defective function of Fas in T cells from paediatric patients with autoimmune thyroid diseases. Clin Exp Immunol. 2003;133:430–437.
105. Masuichi H, Seki S, Kitada T, et al. Significant role of apoptosis in type-1 autoimmune hepatitis. Osaka City Med J. 1999;45:61–79.
106. Canbay A, Taimr P, Torok N, et al. Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest. 2003;83:655–663.
107. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology. 2008;134:1655–1669.
108. Czaja AJ. Review article: Prevention and reversal of hepatic fibrosis in autoimmune hepatitis. Aliment Pharmacol Ther. 2014;39:385–406.
109. Savill J, Dransfield I, Gregory C, Haslett C. A blast from the past: clearance of apoptotic cells regulates immune responses. Nat Rev Immunol. 2002;2:965–975.
110. Canbay A, Higuchi H, Bronk SF, et al. Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. Gastroenterology. 2002;123:1323–1330.
111. Canbay A, Feldstein A, Baskin-Bey E, Bronk SF, Gores GJ. The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse. J Pharmacol Exp Ther. 2004;308:1191–1196.
112. Takehara T, Tatsumi T, Suzuki T, et al. Hepatocyte-specific disruption of Bcl-xL leads to continuous hepatocyte apoptosis and liver fibrotic responses. Gastroenterology. 2004;127:1189–1197.
113. Tsikrikoni A, Kyriakou DS, Rigopoulou EI, et al. Markers of cell activation and apoptosis in bone marrow mononuclear cells of patients with autoimmune hepatitis type 1 and primary biliary cirrhosis. J Hepatol. 2005;42:393–399.
114. Taylor PR, Martinez-Pomares L, Stacey M, et al. Macrophage receptors and immune recognition. Ann Rev Immunol. 2005;23:901–944.
115. Leitinger N. The role of phospholipid oxidation products in inflammatory and autoimmune diseases: evidence from animal models and in humans. Subcell Biochem. 2008;49:325–350.
116. Hanayama R, Tanaka M, Miwa K, et al. Identification of a factor that links apoptotic cells to phagocytes. Nature. 2002;417:182–187.
117. Ravichandran KS, Lorenz U. Engulfment of apoptotic cells: signals for a good meal. Nat Rev Immunol. 2007;7:964–974.
118. Lemke G, Burstyn-Cohen T. TAM receptors and the clearance of apoptotic cells. Ann NY Acad Sci. 2010;1209:23–29.
119. Joseph SB, Castrillo A, Laffitte BA, Mangelsdorf DJ, Tontonoz P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med. 2003;9:213–219.
120. Castrillo A, Tontonoz P. Nuclear receptors in macrophage biology: at the crossroads of lipid metabolism and inflammation. Annu Rev Cell Dev Biol. 2004;20:455–480.
121. Rong GH, Yang GX, Ando Y, et al. Human intrahepatic biliary epithelial cells engulf blebs from their apoptotic peers. Clin Exp Immunol. 2013;172:95–103.
122. Elliott MR, Chekeni FB, Trampont PC, et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature. 2009;461:282–286.
123. Dranoff JA, Ogawa M, Kruglov EA, et al. Expression of P2Y nucleotide receptors and ectonucleotidases in quiescent and activated rat hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol. 2004;287:G417–G424.
124. Nagata S, Hanayama R, Kawane K. Autoimmunity and the clearance of dead cells. Cell. 2010;140:619–630.
125. Li MO, Flavell RA. Contextual regulation of inflammation: a duet by transforming growth factor-beta and interleukin-10. Immunity. 2008;28:468–476.
126. Sun EW, Shi YF. Apoptosis: the quiet death silences the immune system. Pharmacol Ther. 2001;92:135–145.
127. Ghavami S, Hashemi M, Kadkhoda K, et al. Apoptosis in liver diseases—detection and therapeutic applications. Med Sci Monit. 2005;11:RA337–RA345.
128. Sun H, Nikolovska-Coleska Z, Yang CY, et al. Structure-based design, synthesis, and evaluation of conformationally constrained mimetics of the second mitochondria-derived activator of caspase that target the X-linked inhibitor of apoptosis protein/caspase-9 interaction site. J Med Chem. 2004;47:4147–4150.
129. Bedikian AY, Millward M, Pehamberger H, et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol. 2006;24:4738–4745.
130. O’Brien S, Moore JO, Boyd TE, et al. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2007;25:1114–1120.
131. Masuoka HC, Guicciardi ME, Gores GJ. Caspase inhibitors for the treatment of hepatitis C. Clin Liver Dis. 2009;13:467–475.
132. Hoglen NC, Hirakawa BP, Fisher CD, et al. Characterization of the caspase inhibitor IDN-1965 in a model of apoptosis-associated liver injury. J Pharmacol Exp Ther. 2001;297:811–818.
133. Ueno Y, Ohmi T, Yamamoto M, et al. Orally-administered caspase inhibitor PF-03491390 is retained in the liver for prolonged periods with low systemic exposure, exerting a hepatoprotective effect against alpha-fas-induced liver injury in a mouse model. J Pharmacol Sci. 2007;105:201–205.
134. Witek RP, Stone WC, Karaca FG, et al. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis. Hepatology. 2009;50:1421–1430.
135. Anstee QM, Concas D, Kudo H, et al. Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis. J Hepatol. 2010;53:542–550.
136. Yoshida N, Iwata H, Yamada T, et al. Improvement of the survival rate after rat massive hepatectomy due to the reduction of apoptosis by caspase inhibitor. J Gastroenterol Hepatol. 2007;22:2015–2021.
137. Faubel S, Edelstein CL. Caspases as drug targets in ischemic organ injury. Curr Drug Targets Immune Endocr Metab Disord. 2005;5:269–287.
138. Valentino KL, Gutierrez M, Sanchez R, Winship MJ, Shapiro DA. First clinical trial of a novel caspase inhibitor: anti-apoptotic caspase inhibitor, IDN-6556, improves liver enzymes. Int J Clin Pharmacol Ther. 2003;41:441–449.
139. Pockros PJ, Schiff ER, Shiffman ML, et al. Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. Hepatology. 2007;46:324–329.
140. Arends JE, Hoepelman AI, Nanlohy NM, et al. Low doses of the novel caspase-inhibitor GS-9450 leads to lower caspase-3 and -8 expression on peripheral CD4+ and CD8+ T-cells. Apoptosis. 2011;16:959–966.
141. Baskin-Bey ES, Washburn K, Feng S, et al. Clinical trial of the pan-caspase inhibitor, IDN-6556, in human liver preservation injury. Am J Transplant. 2007;7:218–225.
142. Santiago-Raber ML, Baudino L, Izui S. Emerging roles of TLR7 and TLR9 in murine SLE. J Autoimmun. 2009;33:231–238.
143. Lenert PS. Classification, mechanisms of action, and therapeutic applications of inhibitory oligonucleotides for toll-like receptors (TLR) 7 and 9. Mediat Inflamm. 2010;2010:986596.
144. LaCasse EC, Baird S, Korneluk RG, MacKenzie AE. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene. 1998;17:3247–3259.
145. Wang K, Lin B. Inhibitor of apoptosis proteins (IAPs) as regulatory factors of hepatic apoptosis. Cell Signal. 2013;25:1970–1980.
146. Holcik M, Gibson H, Korneluk RG. XIAP: apoptotic brake and promising therapeutic target. Apoptosis. 2001;6:253–261.
147. Zehntner SP, Bourbonniere L, Moore CS, et al. X-linked inhibitor of apoptosis regulates T cell effector function. J Immunol. 2007;179:7553–7560.
148. Jost PJ, Grabow S, Gray D, et al. XIAP discriminates between type I and type II FAS-induced apoptosis. Nature. 2009;460:1035–1039.
149. Mayer BA, Rehberg M, Erhardt A, et al. Inhibitor of apoptosis proteins as novel targets in inflammatory processes. Arterioscler Thromb Vasc Biol. 2011;31:2240–2250.
150. Agrawal S. Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides. Biochim Biophys Acta. 1999;1489:53–68.
151. Hu Y, Cherton-Horvat G, Dragowska V, et al. Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Clin Cancer Res. 2003;9:2826–2836.
152. Chen J, Xiao XQ, Deng CM, Su XS, Li GY. Downregulation of xIAP expression by small interfering RNA inhibits cellular viability and increases chemosensitivity to methotrexate in human hepatoma cell line HepG2. J Chemother. 2006;18:525–531.
153. Gorgani NN, Theofilopoulos AN. Contribution of histidine-rich glycoprotein in clearance of immune complexes and apoptotic cells: implications for ameliorating autoimmune diseases. Autoimmunity. 2007;40:260–266.
154. Baker BF, Monia BP. Novel mechanisms for antisense-mediated regulation of gene expression. Biochim Biophys Acta. 1999;1489:3–18.
155. Cui D, Zhang S, Ma J, Han J, Jiang H. Short interfering RNA targeting NF-kappa B induces apoptosis of hepatic stellate cells and attenuates extracellular matrix production. Dig Liver Dis. 2010;42:813–817.
156. Yonehara S. Death receptor Fas and autoimmune disease: from the original generation to therapeutic application of agonistic anti-Fas monoclonal antibody. Cytokine Growth Factor Rev. 2002;13:393–402.
157. Orzaez M, Gortat A, Mondragon L, Perez-Paya E. Peptides and peptide mimics as modulators of apoptotic pathways. ChemMedChem. 2009;4:146–160.
158. Prinz-Hadad H, Mizrachi T, Irony-Tur-Sinai M, et al. Amelioration of autoimmune neuroinflammation by the fusion molecule Fn14.TRAIL. J Neuroinflamm. 2013;10:36.
159. Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192:1027–1034.
160. Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001;2:261–268.
161. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol. 2007;8:239–245.
162. Dong H, Strome SE, Matteson EL, et al. Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis. J Clin Invest. 2003;111:363–370.
163. Sabapathy K. Role of the JNK pathway in human diseases. Prog Mol Biol Transl Sci. 2012;106:145–169.
164. Minero VG, Khadjavi A, Costelli P, Baccino FM, Bonelli G. JNK activation is required for TNFalpha-induced apoptosis in human hepatocarcinoma cells. Int Immunopharmacol. 2013;17:92–98.
165. Lapierre P, Djilali-Saiah I, Vitozzi S, Alvarez F. A murine model of type 2 autoimmune hepatitis: xenoimmunization with human antigens. Hepatology. 2004;39:1066–1074.
166. Holdener M, Hintermann E, Bayer M, et al. Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection. J Exp Med. 2008;205:1409–1422.
167. Adachi M, Suematsu S, Kondo T, et al. Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver. Nat Genet. 1995;11:294–300.
168. Yue HH, Diehl GE, Winoto A. Loss of TRAIL-R does not affect thymic or intestinal tumor development in p53 and adenomatous polyposis coli mutant mice. Cell Death Differ. 2005;12:94–97.
169. Nakamoto Y, Kaneko S, Fan H, et al. Prevention of hepatocellular carcinoma development associated with chronic hepatitis by anti-fas ligand antibody therapy. J Exp Med. 2002;196:1105–1111.
170. Pfeffer K, Matsuyama T, Kundig TM, et al. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell. 1993;73:457–467.
171. Tinmouth J, Lee M, Wanless IR, et al. Apoptosis of biliary epithelial cells in primary biliary cirrhosis and primary sclerosing cholangitis. Liver. 2002;22:228–234.
172. Macdonald P, Palmer J, Kirby JA, Jones DE. Apoptosis as a mechanism for cell surface expression of the autoantigen pyruvate dehydrogenase complex. Clini Exp Immunol. 2004;136:559–567.
173. Lleo A, Selmi C, Invernizzi P, et al. Apotopes and the biliary specificity of primary biliary cirrhosis. Hepatology. 2009;49:871–879.
174. Lleo A, Bowlus CL, Yang GX, et al. Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis. Hepatology. 2010;52:987–998.
175. Rong G, Zhong R, Lleo A, et al. Epithelial cell specificity and apotope recognition by serum autoantibodies in primary biliary cirrhosis. Hepatology. 2011;54:196–203.
176. Greystoke A, Cummings J, Ward T, et al. Optimisation of circulating biomarkers of cell death for routine clinical use. Ann Oncol. 2008;19:990–995.
177. Bantel H, Ruck P, Gregor M, Schulze-Osthoff K. Detection of elevated caspase activation and early apoptosis in liver diseases. Eur J Cell Biol. 2001;80:230–239.
178. Hiley C, Fryer A, Bell J, Hume R, Strange RC. The human glutathione S-transferases. Immunohistochemical studies of the developmental expression of alpha- and pi-class isoenzymes in liver. Biochem J. 1988;254:255–259.
179. Denk G, Omary AJ, Reiter FP, et al. sICAM, M30, and M65 as serum markers of disease activity and prognosis in cholestatic liver diseases. Hepatol Res. 2014;. doi:10.1111/hepr.12304.